Clinical Trial Detail

NCT ID NCT03728972
Title Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

mature T-cell and NK-cell lymphoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.